Printer Friendly

BIOSPECIFICS TECHNOLOGIES RECEIVES CLINICAL TRIAL EXEMPTION FOR COLLAGENASE OINTMENT IN ENGLAND

 LYNBROOK, N.Y., March 3 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that its collagenase-based ointment has received Clinical Trial Exemption (CTX) in England. The company will now begin clinical trials of the ointment in the United Kingdom to gather statistical evidence to present to governmental authorities for marketing approval. The trials will occur at a leading institution in Great Britain. The ointment is used to treat dermal ulcers (including bed sores) and burns and has the approval of the FDA.
 This collagenase ointment is already sold in the United States under the trademark Santyl Ointment. Sales have been growing at an explosive pace in the U.S., yet market penetration has reached only 1 percent of patients afflicted with bed sores alone. BioSpecifics Technologies anticipates reaching up to 25 percent of this market in the next few years.
 Initial clinical trials of collagenase ointment in the treatment of deep second degree burns has been expanded to four burn centers after the initial clinical trials were done at Stonybrook University, N.Y., under the direction of Harry Soroff, M.D., chief of the Burn Unit. These initial results indicated a substantial savings in the time required to heal lesions treated with Collagenase as compared to Silvadene, the standard treatment.
 BioSpecifics produces and licenses pharmaceutical products for domestic and international sales. The company is also engaged in various stages of research, development, clinical testing and marketing of additional pharmaceutical products and therapeutically-active molecules. The company's current principal product is its FDA-approved enzyme, Collagenase ABC, used in topical applications for treatment of dermal ulcers and severely burned areas.
 -0- 3/3/93
 /CONTACT: Edwin H. Wegman, chairman of BioSpecifics, 516-593-7000; Sam Witchel of Scharff, Witchel & Co., Inc., 212-983-1060, for BioSpecifics Technologies Corp./
 (BSTC)


CO: BioSpecifics Technologies Corp. ST: New York IN: MTC SU:

AH-SH -- NY031 -- 2401 03/03/93 11:10 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1993
Words:311
Previous Article:AMERIHOST ENTERS HOTEL DEVELOPMENT AGREEMENT WITH RICHMARK INNS
Next Article:$396 BILLION OF TRUSTEED DEBT ISSUED IN '92; CITIBANK MAINTAINS LEADING TRUSTEE POSITION
Topics:


Related Articles
BIOSPECIFICS ANNOUNCES EXPANSION OF CLINICAL TRIALS FOR OINTMENT
RESEARCH TESTING OF COLLAGENASE ON PEYRONIE'S DISEASE PATIENTS SHOWS POSITIVE RESULTS
BIOSPECIFICS TECHNOLOGIES CORP. LICENSEE RECEIVES MARKETING APPROVAL OF COLLAGENASE OINTMENT IN INDIA
BIOSPECIFICS TECHNOLOGIES CORP.'S COLLAGENASE CHOSEN AS A PREFERRED TREATMENT OF PRESSURE SORES BY FEDERAL GOVERNMENT HEALTH AGENCY
BIOSPECIFICS TECHNOLOGIES CORP., ANNOUNCES SEVEN MAJOR U.S. BURN CENTERS TO PARTICIPATE IN CLINICAL TRIALS OF HIGH POTENCY BURN TREATMENT
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL COMPLETION OF NUCLEOLYSIN CLINICAL TRIAL IN ITALY
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL COMPLETION IN UNITED KINGDOM OF CLINICAL STUDY OF COLLAGENASE OINTMENT FOR TREATMENT OF PRESSURE...
BIOSPECIFICS TECHNOLOGIES CORP. ANNOUNCES SUCCESSFUL ITALIAN CLINICAL TRIALS
BioSpecifics Announces Phase 2 Start of Dupuytren's Disease Study With Cordase(TM) Injectable Collagenase

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters